BPC
DYN icon

Bryce Point Capital’s Dyne Therapeutics DYN Stock Holding History

Bryce Point Capital’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12,055
Closed -$115K – 195
2025
Q2 		$115K Buy
+12,055
New +$133K 0.1% 177

Other funds holding DYN

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Bryce Point Capital's DYN Position: Q3 2025 in Review

Bryce Point Capital sold out of Dyne Therapeutics (DYN) in Q3 2025, closing a stake of 12,055 shares — an estimated $115K sold.

Bryce Point Capital first reported a position in DYN in Q2 2025 and held it in 1 quarter. The position peaked at $115K in Q2 2025. 207 funds tracked by Wall St. Rank hold DYN as of Q3 2025.

  • Bryce Point Capital reported no remaining Dyne Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Bryce Point Capital sold 12,055 Dyne Therapeutics shares in Q3 2025, an estimated $115K.
  • Bryce Point Capital first reported a position in Dyne Therapeutics in Q2 2025 and held it in 1 quarter.
  • Bryce Point Capital's Dyne Therapeutics position peaked at $115K in Q2 2025.
  • 207 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q3 2025.

Based on Bryce Point Capital's 13F filing for Q3 2025, filed 6 Nov 2025.